Dengue virus (DENV) is the causative agent of dengue fever and dengue hemorrhagic fever. The virus is endemic in over 120 countries, causing over 350 million infections per year.
Dengue vaccine development is challenging because of the need to induce simultaneous protection against four antigenically distinct DENV serotypes and evidence that, under some conditions, vaccination can enhance disease due to specific immunity to the virus. While several live-attenuated tetravalent dengue virus vaccines display partial efficacy, it has been challenging to induce balanced protective immunity to all 4 serotypes. Instead of using whole-virus formulations, we are exploring the potentials for a particulate subunit vaccine, based on DENV E-protein displayed on nanoparticles that have been precisely molded using Particle Replication in Non-wetting Template (PRINT) technology.
Here we describe immunization studies with a DENV2-nanoparticle vaccine candidate. The ectodomain of DENV2-E protein was expressed as a secreted recombinant protein (sRecE), purified and adsorbed to poly (lactic-co-glycolic acid) (PLGA) nanoparticles of different sizes and shape. We show that PRINT nanoparticle adsorbed sRecE without any adjuvant induces higher IgG titers and a more potent DENV2-specific neutralizing antibody response compared to the soluble sRecE protein alone. Antigen trafficking indicate that PRINT nanoparticle display of sRecE prolongs the bio-availability of the antigen in the draining lymph nodes by creating an antigen depot. Our results demonstrate that PRINT nanoparticles are a promising platform for delivering subunit vaccines against flaviviruses such as dengue and Zika.
Dengue virus (DENV) is transmitted by mosquitoes and is endemic in over 120 countries, causing over 350 million infections yearly. Most infections are clinically unapparent, but under specific conditions, dengue can cause severe and lethal disease. DENV has 4 distinct serotypes and secondary DENV infections are associated with hemorrhagic fever and dengue shock syndrome. This enhancement of infection complicates vaccine development and makes it necessary to induce protective immunity against all 4 serotypes. Since whole virus vaccine candidates struggle to induce protective immunity, we are developing a nanoparticle display vaccine approach. We have expressed, purified and characterized a soluble recombinant E-protein (sRecE). Regardless of nanoparticle shape or size, particulation of sRecE enhances DENV specific IgG titers and induces a robust, long lasting neutralizing antibody response and by adsorbing sRecE to the nanoparticles, we prolong the exposure of sRecE to the immune system.
Nanoparticle display shows great promise in dengue vaccine development and possibly other mosquito-borne viruses like zika virus.
The Latest on: Nanoparticle vaccines
via Google News
The Latest on: Nanoparticle vaccines
- Genetic Immunity Grants Exclusive License of Therapeutic HIV Vaccine Technology to JSC Pharmadis for Russia and Commonwealth of Independent States on December 18, 2018 at 1:45 am
The vaccine is administered topically using the ... The formulation of plasmid DNA to a pathogen-like nanoparticle called NanoComp. These nanoparticles target professional antigen-presenting ... […]
- Basic Science Tip Sheet on November 15, 2018 at 6:17 pm
Nanoparticles show early promise in reducing inflammation after brain bleed. Alcohol exposure before birth may later amplify neurological problems from stroke. Vaccine shows potential to protect the b... […]
- Emergex Demonstrates Excellent Safety Profile for Gold Nanoparticle Used in its Vaccine Platform on October 24, 2018 at 1:27 am
OXFORD, England--(Business Wire)--Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to synthetic vaccine development in the field of infectious diseases, ... […]
- New Nanoparticle-Based Vaccine Protects against Anthrax and Plague on October 17, 2018 at 2:03 am
A research team in the United States has developed a nanoparticle-based dual vaccine against Bacillus anthracis and Yersinia pestis — pathogens that cause anthrax and plague, respectively. Vaccines ar... […]
- Researchers engineer dual vaccine against anthrax and plague on October 16, 2018 at 3:16 am
Washington, DC - October 16, 2018 - A team of researchers has now engineered a virus nanoparticle vaccine against Bacillus anthracis and Yersinia pestis, tier 1 agents that pose serious threats to nat... […]
- 5 Stocks Rated Buy Under $10 With Huge Upside Potential on September 22, 2018 at 12:15 am
Novavax Inc. (NASDAQ: NVAX) is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. It operates through deve... […]
- Novel Nanoparticle Vaccine Protects against Influenza A Virus in Animal Study on August 1, 2018 at 2:02 am
Dr. Bao-Zhong Wang of the Institute for Biomedical Sciences at Georgia State University and colleagues have developed an experimental nanoparticle vaccine against influenza A virus that seems to work ... […]
- American, Chinese scientists develop preliminary universal vaccine on July 30, 2018 at 12:56 pm
(REUTERS/ Photo) WASHINGTON, July 30 (Xinhua) -- American and Chinese scientists developed a new nanoparticle vaccine that could effectively protect mice against influenza A virus, according to a stud... […]
- Nanoparticle vaccine made with peptides effective against influenza virus, study finds on July 30, 2018 at 12:03 pm
A new, double-layered nanoparticle vaccine made with peptides has been found to effectively protect mice against influenza A virus, according to a study led by Georgia State University. Influenza, a c... […]
via Bing News